India,China eye growth potential in biosimilars as US stalls on legislation

摘要

With the passage of new patent laws in their countries,India and China will be well-poised to accelerate their pharmaceutical industries,especially biopharmaceuticals,according to a new research study released by industry research firm,Kalorama Information.According to the report titled'Pharmaceutical markets in Brazil,Russia,India and China(BRIC nations),'companies in India and China are placing themselves in a good position to compete worldwide with developers of innovative biological products.